Publications by authors named "C Dentone"
Article Synopsis
- The study examines T-cell characteristics in individuals with perinatal HIV (PHIV), adults with HIV (AHIV), and healthy controls, focusing on activation, exhaustion, and regulatory T-cell frequencies.
- It involved a cross-sectional analysis of young people with controlled HIV and healthy individuals, using various immunological markers to identify differences between groups.
- Results showed PHIV had a healthier T-cell profile with lower exhaustion markers and higher naive T-cell frequencies than AHIV, suggesting that the timing of HIV infection influences immune system status.
New therapies and vaccines changed the management of COVID-19. The aim of this retrospective study was to describe characteristics, in-hospital mortality and its predictors in patients with moderate/severe COVID-19, considering the 4 different pandemic waves and viral variants' prevalence from February 2020 to January 2022. Among 1135 patients included, 873 (77%) had at least one comorbidity, 177 (16%) were immunocompromised.
View Article and Find Full Text PDFBackground: Isavuconazole is first-line treatment of invasive aspergillosis. Therapeutic drug monitoring (TDM) is deemed not necessary, since most patients reached therapeutic levels (>1 mg/L) in large studies. Low levels were reported in some critically ill patients admitted to the ICU.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on comparing hospitalized vaccinated and non-vaccinated patients diagnosed with SARS-CoV-2 in three major hospitals in Northern Italy, investigating their clinical characteristics and outcomes.
- Data analysis highlighted that vaccinated patients, despite having more serious underlying health issues, generally had milder COVID-19 symptoms and required less intensive care compared to non-vaccinated patients.
- No significant difference in intra-hospital mortality rates was found between the two groups, indicating vaccination effectively reduces the likelihood of ICU admission but does not significantly impact overall survival rates in the hospital.
Among treatment options for Coronavirus disease 2019 (COVID-19), monoclonal antibodies (mAbs) showed to be effective in preventing disease progression, but real-world data during the Omicron variant surge are still lacking. Multicentre retrospective study evaluating the effectiveness of sotrovimab and casirivimab-imdevimab in fragile patients with mild SARS-CoV-2 infection between November 2021 and March 2022. Unfavourable outcome was defined as increased need for oxygen supplementation and/or death.
View Article and Find Full Text PDF